Cancers (Dec 2018)
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
- Michael P. Lux,
- Naiba Nabieva,
- Andreas D. Hartkopf,
- Jens Huober,
- Bernhard Volz,
- Florin-Andrei Taran,
- Friedrich Overkamp,
- Hans-Christian Kolberg,
- Peyman Hadji,
- Hans Tesch,
- Lothar Häberle,
- Johannes Ettl,
- Diana Lüftner,
- Markus Wallwiener,
- Volkmar Müller,
- Matthias W. Beckmann,
- Erik Belleville,
- Pauline Wimberger,
- Carsten Hielscher,
- Matthias Geberth,
- Wolfgang Abenhardt,
- Christian Kurbacher,
- Rachel Wuerstlein,
- Christoph Thomssen,
- Michael Untch,
- Peter A. Fasching,
- Wolfgang Janni,
- Tanja N. Fehm,
- Diethelm Wallwiener,
- Andreas Schneeweiss,
- Sara Y. Brucker
Affiliations
- Michael P. Lux
- Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University of Erlangen–Nuremberg, Universitätsstrasse 21–23, 91054 Erlangen, Germany
- Naiba Nabieva
- Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University of Erlangen–Nuremberg, Universitätsstrasse 21–23, 91054 Erlangen, Germany
- Andreas D. Hartkopf
- Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany
- Jens Huober
- Department of Gynecology and Obstetrics, Ulm University Hospital, 89070 Ulm, Germany
- Bernhard Volz
- Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University of Erlangen–Nuremberg, Universitätsstrasse 21–23, 91054 Erlangen, Germany
- Florin-Andrei Taran
- Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany
- Friedrich Overkamp
- Oncologianova GmbH, 45657 Recklinghausen, Germany
- Hans-Christian Kolberg
- Marienhospital Bottrop, 46236 Bottrop, Germany
- Peyman Hadji
- Department of Bone Oncology, Nordwest Hospital, 60488 Frankfurt, Germany
- Hans Tesch
- Oncology Practice at Bethanien Hospital Frankfurt; 60389 Frankfurt, Germany
- Lothar Häberle
- Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University of Erlangen–Nuremberg, Universitätsstrasse 21–23, 91054 Erlangen, Germany
- Johannes Ettl
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
- Diana Lüftner
- Charité University Hospital, Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumour Immunology, 12203 Berlin, Germany
- Markus Wallwiener
- Department of Obstetrics and Gynecology, University of Heidelberg, 69120 Heidelberg, Germany
- Volkmar Müller
- Department of Gynecology, Hamburg-Eppendorf University Medical Center, 20246 Hamburg, Germany
- Matthias W. Beckmann
- Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University of Erlangen–Nuremberg, Universitätsstrasse 21–23, 91054 Erlangen, Germany
- Erik Belleville
- ClinSol GmbH & Co KG, 97074 Würzburg, Germany
- Pauline Wimberger
- Department of Gynecology and Obstetrics, Dresden University Hospital, 01307 Dresden, Germany
- Carsten Hielscher
- gSUND Gynäkologie Kompetenzzentrum Stralsund, 18435 Stralsund, Germany
- Matthias Geberth
- Gynäkologische Praxisklinik am Rosengarten, 68165 Mannheim, Germany
- Wolfgang Abenhardt
- Medizinischen Versorgungszentrum Onkologie, Onkologie im Elisenhof, 80335 Munich, Germany
- Christian Kurbacher
- Department of Gynecology and Obstetrics, Medizinisches Zentrum Bonn Friedensplatz, 53111 Bonn, Germany
- Rachel Wuerstlein
- Department of Gynecology and Obstetrics, Breast Center and Comprehensive Cancer Center Munich, Munich University Hospital, 80337 Munich, Germany
- Christoph Thomssen
- Department of Gynecology, Martin Luther University of Halle-Wittenberg, 06120 Halle (Saale), Germany
- Michael Untch
- Department of Gynecology and Obstetrics, Helios Clinics Berlin Buch, 13125 Berlin, Germany
- Peter A. Fasching
- Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University of Erlangen–Nuremberg, Universitätsstrasse 21–23, 91054 Erlangen, Germany
- Wolfgang Janni
- Department of Gynecology and Obstetrics, Ulm University Hospital, 89070 Ulm, Germany
- Tanja N. Fehm
- Department of Gynecology and Obstetrics, Düsseldorf University Hospital, 40225 Düsseldorf, Germany
- Diethelm Wallwiener
- Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany
- Andreas Schneeweiss
- Department of Obstetrics and Gynecology, University of Heidelberg, 69120 Heidelberg, Germany
- Sara Y. Brucker
- Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany
- DOI
- https://doi.org/10.3390/cancers11010010
- Journal volume & issue
-
Vol. 11,
no. 1
p. 10
Abstract
This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns with trastuzumab (H), pertuzumab + trastuzumab (PH), lapatinib (L), and trastuzumab emtansine (T-DM1). The PRAEGNANT study is a real-time, real-world registry for MBC patients. All therapy lines are documented. This analysis describes the utilization of anti-HER2 therapies as well as therapy sequences. Among 1936 patients in PRAEGNANT, 451 were HER2-positive (23.3%). In the analysis set (417 patients), 53% of whom were included in PRAEGNANT in the first-line setting, 241 were treated with H, 237 with PH, 85 with L, and 125 with T-DM1 during the course of their therapies. The sequence PH → T-DM1 was administered in 51 patients. Higher Eastern Cooperative Oncology Group (ECOG) scores, negative hormone receptor status, and visceral or brain metastases were associated with more frequent use of this therapy sequence. Most patients received T-DM1 after treatment with pertuzumab. Both novel therapies (PH and T-DM1) are utilized in a high proportion of HER2-positive breast cancer patients. As most patients receive T-DM1 after PH, real-world data may help to clarify whether the efficacy of this sequence is similar to that in the approval study.
Keywords
- advanced breast cancer
- metastatic
- chemotherapy
- antihormone therapy
- HER2 c-erbB2
- HER2/neu
- trastuzumab
- pertuzumab
- T-DM1
- lapatinib